Generic Name and Formulations:
Vismodegib 150mg; caps.
Indications for ERIVEDGE:
Treatment of adults with metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.
Swallow whole. 150mg once daily, until disease progression or unacceptable toxicity.
Risk of embryo-fetal death and severe birth defects in pregnant women. Verify pregnancy status within 7 days prior to initiation of therapy. Females of reproductive potential should use effective contraception during therapy and for 24 months after final dose; male patients should use condoms (even after a vasectomy) during and for 3 months after final dose. Advise patients not to donate blood or blood products during therapy and for 24 months after final dose. Advise male patients not to donate semen during and for 3 months after final dose. Premature fusion of the epiphyses may occur in pediatrics if exposed. Pregnancy: avoid. Nursing mothers: not recommended (during and for 24 months after final dose).
Hedgehog pathway inhibitor.
Muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, vomiting, decreased appetite, constipation, arthralgias, ageusia; amenorrhea.
Report immediately exposure to Erivedge during pregnancy by contacting the Genentech Adverse Event Line at (888) 835-2555.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Evidence of Methylphenidate Abuse: Characterizing Patterns of Use in Pediatric and Adult Populations
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- Most Patients Comfortable With Clinicians Asking About Sexual Orientation
- Peer-to-Peer Depression Awareness Program May Be Beneficial
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders